首页>外文期刊>其他>Investigational New Drugs

Investigational New Drugs

Investigational New Drugs

中文名称：研究性新药

ISSN：0167-6997
出版周期：Quarterly

发文量：951

期刊论文

年度选择

2023
- 第1期
- 第2期
- 第3期
2022
- 第2期
- 第3期
- 第4期
- 第5期
- 第6期
2017
- 第1期
- 第3期
- 第4期
- 第6期
2016
- 第1期
- 第3期
2015
- 第1期
- 第2期
- 第3期
- 第4期
- 第5期
- 第6期
2014
- 第1期
- 第3期
- 第4期
- 第6期
2013
- 第1期
- 第4期
- 第6期
2012
- 第1期
- 第2期
- 第3期
- 第4期
- 第5期
- 第6期
2011
- 第1期
- 第2期
- 第3期
- 第4期
- 第5期
- 第6期
2010
- 第1期
- 第2期
- 第3期
- 第4期
- 第5期
- 第6期
- 第s1期
2009
- 第1期
- 第6期
2008
- 第1期
- 第2期
- 第3期
- 第4期
- 第5期
- 第6期
2007
- 第1期
- 第2期
- 第3期
- 第4期
- 第5期
- 第6期
2006
- 第1期
- 第2期
- 第3期
- 第4期
- 第5期
- 第6期
2005
- 第1期
- 第2期
- 第3期
- 第4期
- 第5期
- 第6期
2004
- 第1期
- 第2期
- 第3期
- 第4期
2003
- 第1期
- 第2期
- 第3期
- 第4期
2002
- 第1期
- 第2期
- 第3期
- 第4期
2001
- 第1期
- 第2期
- 第3期
- 第4期

更多>>

全选（0）

1.Immunohistochemical analysis of B7-H3 expression in patients with lung cancer following various anti-cancer treatments

机译：Immunohistochemical analysis of B7-H3 expression in patients with lung cancer following various anti-cancer treatments
- 作者：ShotaOmori;KojiMuramatsu;TakuyaKawataErikoMiyawakiTaichiMiyawakiNobuakiMamesayaTakahisaKawamuraHarukiKobayashiKazuhisaNakashimaKazushigeWakudaAkiraOnoHirotsuguKenmotsuTateakiNaitoHaruyasuMurakamiTakashiSuginoToshiakiTakahashi
- 期刊名称：《Investigational new drugs.》 | 2023年第2期
- Immune checkpoint proteins;
- Squamous cell carcinoma;
- Immunohistochemistry;
- Chemotherapy;
- Epidermal growth factor receptor;
2.Combination carboplatin and nab-paclitaxel as a first-line treatment for advanced thymic carcinoma

机译：Combination carboplatin and nab-paclitaxel as a first-line treatment for advanced thymic carcinoma
- 作者：Manaka Hiroya;Igawa Satoshi;Yamamoto MichikoOguri AkitoManabe HideakiKasajima MasashiKusuhara SeiichiroHosotani ShinjiNakahara YoshiroSato TakashiFukui TomoyaHisashi MitsufujiSasaki JiichiroNaoki Katsuhiko
- 期刊名称：《Investigational new drugs.》 | 2023年第1期
- Thymic carcinoma;
- Carboplatin;
- Nab-paclitaxel;
- Efficacy;
- PHASE-II;
- MAINTENANCE MONOTHERAPY;
- RETROSPECTIVE ANALYSIS;
- CHEMOTHERAPY;
- LENVATINIB;
- CISPLATIN;
- CANCER;
- VINCRISTINE;
- MULTICENTER;
- DOXORUBICIN;
3.IMB5036, a novel pyridazinone compound, inhibits hepatocellular carcinoma growth and metastasis

机译：IMB5036, a novel pyridazinone compound, inhibits hepatocellular carcinoma growth and metastasis
- 作者：Lv Xing;Zhao Qi;Dong YanqunYang LijunGong JianhuaZheng YanboYang Tao
- 期刊名称：《Investigational new drugs.》 | 2022年第3期
- Hepatocellular carcinoma;
- IMB5036;
- Apoptosis;
- E-cadherin;
- Tau protein;
- DOUBLE-STRAND BREAKS;
- E-CADHERIN;
- DNA;
- SORAFENIB;
- MOTILITY;
- CELLS;
- TAU;
4.Advances in glioma-associated oncogene (GLI) inhibitors for cancer therapy

机译：Advances in glioma-associated oncogene (GLI) inhibitors for cancer therapy
- 作者：Zhang Meng;Gao Lijuan;Ye YipingLi Xiaoyu
- 期刊名称：《Investigational new drugs.》 | 2022年第2期
5.SLIT mutations as potential predictive biomarkers for immunotherapy in NSCLC

机译：SLIT mutations as potential predictive biomarkers for immunotherapy in NSCLC
- 作者：TongZhou;HuanYi;ChanZhuYangyangYuQianruHeMingzheXiaoChuangQiTianyuLu
- 期刊名称：《Investigational new drugs.》 | 2023年第2期
6.Lenvatinib combined with nivolumab in advanced hepatocellular carcinoma-real-world experience

机译：Lenvatinib combined with nivolumab in advanced hepatocellular carcinoma-real-world experience
- 作者：Wu Wen-Chi;Lin Tzu-Yuan;Chen Ming-HuangHung Yi-PingLiu Chien-AnLee Rheun-ChuanHuang Yi-HsiangChao YeeChen San-Chi
- 期刊名称：《Investigational new drugs.》 | 2022年第4期
7.AM22, a novel synthetic microRNA, inhibits the proliferation of colorectal cancer cells by targeting core binding factor subunit beta (CBFB)

机译：AM22, a novel synthetic microRNA, inhibits the proliferation of colorectal cancer cells by targeting core binding factor subunit beta (CBFB)
- 作者：Meng Fanyi;Li Jiawei;Qiu YajingZhang HaiyangZhang HongjianWang Weipeng
- 期刊名称：《Investigational new drugs.》 | 2022年第3期
- MicroRNA;
- Single nucleotide alteration;
- Synthetic analogs;
- CBFB;
- Antitumor activity;
- MIR-34A;
- INVASION;
8.Risk factors for severe immune-related adverse events after first-line pembrolizumab monotherapy or combination chemotherapy for non-small-cell lung cancer

机译：Risk factors for severe immune-related adverse events after first-line pembrolizumab monotherapy or combination chemotherapy for non-small-cell lung cancer
- 作者：Sumi Toshiyuki;Koshshino Yuta;Sekikawa MotokiNagahisa YutaMatsuura KeigoShijubou NaokiKamada KokiWatanabe HirokiMichimata HaruhikoNagayama DaikiTanaka YusukeYamada YuichiChiba Hirofumi
- 期刊名称：《Investigational new drugs.》 | 2022年第6期
9.Efficacy and safety of mitoxantrone hydrochloride liposome injection in Chinese patients with advanced breast cancer: a randomized, open-label, active-controlled, single-center, phase II clinical trial

机译：Efficacy and safety of mitoxantrone hydrochloride liposome injection in Chinese patients with advanced breast cancer: a randomized, open-label, active-controlled, single-center, phase II clinical trial
- 作者：Wang Leiping;Cao Jun;Li ChunleiWang XiaodongZhao YannanLi TingDu YiqunTao ZhonghuaPeng WenxiaWang BiyunZhang JianZhang ShengWang ZhonghuaHu Xichun
- 期刊名称：《Investigational new drugs.》 | 2022年第2期
- Breast neoplasms;
- Mitoxantrone;
- Liposomes;
- Efficacy;
- Safety;
- 1ST-LINE TREATMENT;
- PHARMACOKINETICS;
- CARDIOTOXICITY;
- ENCAPSULATION;
- FLUOROURACIL;
- DOXORUBICIN;
- GUIDELINES;
- RETENTION;
10.Brigatinib pharmacokinetics in patients with chronic hepatic impairment

机译：Brigatinib pharmacokinetics in patients with chronic hepatic impairment
- 作者：Hanley Michael J.;Kerstein David;Tugnait MeeraNarasimhan NarayanaMarbury Thomas C.Venkatakrishnan KarthikGupta Neeraj
- 期刊名称：《Investigational new drugs.》 | 2023年第3期
- Brigatinib;
- Anaplastic lymphoma kinase;
- Tyrosine kinase inhibitor;
- Non-small cell lung cancer;
- Pharmacokinetics;
- Hepatic impairment;
- EML4-ALK FUSION GENE;
- CELL LUNG-CANCER;
- CRIZOTINIB;
- INHIBITOR;
- SAFETY;
- EGFR;
11.Early experience of atezolizumab plus bevacizumab therapy in Japanese patients with unresectable hepatocellular carcinoma in real-world practice

机译：Early experience of atezolizumab plus bevacizumab therapy in Japanese patients with unresectable hepatocellular carcinoma in real-world practice
- 作者：Hayakawa Yuka;Tsuchiya Kaoru;Kurosaki MasayukiYasui YutakaKaneko ShunTanaka YukiIshido ShunInada KentoKirino SakuraYamashita KojiNobusawa TsubasaMatsumoto HiroakiKakegawa TatsuyaHiguchi MayuTakaura KentaTanaka ShoheiMaeyashiki ChiakiTamaki NobuharuNakanishi HiroyukiItakura JunTakahashi YukaAsahina YasuhiroOkamoto RyuichiIzumi Namiki
- 期刊名称：《Investigational new drugs.》 | 2022年第2期
- Hepatocellular carcinoma;
- Atezolizumab;
- Bevacizumab;
- Later-line;
- Alpha-fetoprotein;
- SORAFENIB;
- EFFICACY;
12.Bispecific anti-CD3xanti-CD155 antibody mediates T-cell immunotherapy in human haematologic malignancies

机译：Bispecific anti-CD3xanti-CD155 antibody mediates T-cell immunotherapy in human haematologic malignancies
- 作者：Ma Li;Ma Juan;Sun XinLiu Honggang
- 期刊名称：《Investigational new drugs.》 | 2023年第3期
- CD155;
- Bispecific antibody;
- Haematologic malignancy;
- Immunotherapy;
- THERAPIES;
13.Efficacy and safety of amrubicin monotherapy after atezolizumab plus carboplatin and etoposide in patients with relapsed small-cell lung cancer

机译：Efficacy and safety of amrubicin monotherapy after atezolizumab plus carboplatin and etoposide in patients with relapsed small-cell lung cancer
- 作者：Imai Hisao;Nagai Yoshiaki;Minemura HiroyukiTsuda TakeshiYamada YutakaWasamoto SatoshiKishikawa TakayukiShiono AyakoShiihara JunYamaguchi OuMouri AtsutoKaira KyoichiKanazawa KenyaTaniguchi HirokazuMinato KoichiKagamu Hiroshi
- 期刊名称：《Investigational new drugs.》 | 2022年第5期
14.Real-world data of off-label drug use in patients with actionable genomic alterations on next-generation sequencing

机译：Real-world data of off-label drug use in patients with actionable genomic alterations on next-generation sequencing
- 作者：Souza Gabriel Roman;Abdalla Ahmed;Arora SukeshiMahadevan Daruka
- 期刊名称：《Investigational new drugs.》 | 2022年第3期
- Off-label drug use;
- Next-generation sequencing;
- TP53;
- PD-L1;
- Immune checkpoint inhibitors;
- Cancer drugs;
- PEMBROLIZUMAB;
- MUTATIONS;
15.A phase II study of sapanisertib (TAK-228) a mTORC1/2 inhibitor in rapalog-resistant advanced pancreatic neuroendocrine tumors (PNET): ECOG-ACRIN EA2161

机译：A phase II study of sapanisertib (TAK-228) a mTORC1/2 inhibitor in rapalog-resistant advanced pancreatic neuroendocrine tumors (PNET): ECOG-ACRIN EA2161
- 作者：Rajdev Lakshmi;Lee Ju-Whei;Libutti Steven K.Benson Al B.Fisher George A. Jr.Kunz Pamela L.Hendifar Andrew E.Catalano PaulODwyer Peter J.
- 期刊名称：《Investigational new drugs.》 | 2022年第6期
- PNET;
- mTORC1;
- 2 inhibitor;
- Sapanisertib;
- DUAL TORC1/2 INHIBITOR;
- MULTIPLE-MYELOMA;
- FORMERLY MLN0128;
- PATHWAY;
- EVEROLIMUS;
- TARGET;
- TRANSLATION;
- ACTIVATION;
- INITIATION;
- MUTATIONS;
16.HLX22, an anti-HER-2 monoclonal antibody, in patients with advanced solid tumors overexpressing human epidermal growth factor receptor 2: an open-label, dose-escalation, phase 1 trial

机译：HLX22, an anti-HER-2 monoclonal antibody, in patients with advanced solid tumors overexpressing human epidermal growth factor receptor 2: an open-label, dose-escalation, phase 1 trial
- 作者：Zhu Xiaoxue;Ding Yanhua;Wang QianYang GuiyuZhou LiangWang Qingyu
- 期刊名称：《Investigational new drugs.》 | 2023年第3期
- Advanced solid tumors overexpressing HER2;
- HER2 monoclonal antibody;
- HLX22;
- Phase 1 study;
- HER2-POSITIVE BREAST-CANCER;
- SERUM HER2;
- TRASTUZUMAB;
- RESISTANCE;
- PERTUZUMAB;
17.Combination of TACE and Lenvatinib as a promising option for downstaging to surgery of initially unresectable intrahepatic cholangiocarcinoma (vol 40, pg 1125, 2022)

机译：Combination of TACE and Lenvatinib as a promising option for downstaging to surgery of initially unresectable intrahepatic cholangiocarcinoma (vol 40, pg 1125, 2022)
- 作者：Yuan Peng;Song Jinhua;Wang FeiZhu GuangyuChen Baoan
- 期刊名称：《Investigational new drugs.》 | 2023年第1期
18.An exploration of trifluridine/tipiracil in combination with irinotecan in patients with pretreated advanced gastric cancer

机译：An exploration of trifluridine/tipiracil in combination with irinotecan in patients with pretreated advanced gastric cancer
- 作者：Mizukami Takuro;Minashi Keiko;Hara HirokiNishina TomohiroAmanuma YusukeTakahashi NaokiNakasya AkioTakahashi MasakiNakajima Takako Eguchi
- 期刊名称：《Investigational new drugs.》 | 2022年第3期
- Gastric cancer;
- Trifluridine;
- tipiracil;
- TAS-102;
- Irinotecan;
- CPT-11;
- RANDOMIZED PHASE-III;
- 3RD-LINE TREATMENT;
- JAPANESE PATIENTS;
- SUPPORTIVE CARE;
- NAB-PACLITAXEL;
- DOUBLE-BLIND;
- OPEN-LABEL;
- CHEMOTHERAPY;
- PLUS;
19.Effect of a moderate CYP3A inducer efavirenz on the pharmacokinetics of fuzuloparib: An open-label, fixed sequence study in Chinese healthy male subjects

机译：Effect of a moderate CYP3A inducer efavirenz on the pharmacokinetics of fuzuloparib: An open-label, fixed sequence study in Chinese healthy male subjects
- 作者：LinlinHu;TingDou;QiuyueSunLuTangMingminCaiWeiQianHuipingWang
- 期刊名称：《Investigational new drugs.》 | 2023年第2期
20.Signature constructed by glycolysis-immune-related genes can predict the prognosis of osteosarcoma patients

机译：Signature constructed by glycolysis-immune-related genes can predict the prognosis of osteosarcoma patients
- 作者：Tian Kangsong;Qi Wei;Yan QianLv MingSong Delei
- 期刊名称：《Investigational new drugs.》 | 2022年第4期
- Osteosarcoma;
- Prognosis;
- Glycolysis;
- Immune;
- Risk score;
- CELL-PROLIFERATION;
- INHIBITION;
- PROMOTES;
21.Radiosensitizing effect of galunisertib, a TGF-ss receptor I inhibitor, on head and neck squamous cell carcinoma in vitro

机译：Radiosensitizing effect of galunisertib, a TGF-ss receptor I inhibitor, on head and neck squamous cell carcinoma in vitro
- 作者：Jank Bernhard J.;Lenz Teresa;Haas MarkusKadletz-Wanke LorenzCampion Nicholas J.Schnoell JuliaHeiduschka GregorMacfelda Karin
- 期刊名称：《Investigational new drugs.》 | 2022年第3期
- Head and neck squamous cell carcinoma;
- Galunisertib;
- Radiosensitivity;
- TGF-ss;
- GROWTH-FACTOR-BETA;
- TUMOR MICROENVIRONMENT;
- CANCER;
- RESISTANCE;
- RADIORESISTANCE;
- EXPRESSION;
- LY2157299;
22.A small molecule inhibitor of VSIG-8 prevents its binding to VISTA

机译：A small molecule inhibitor of VSIG-8 prevents its binding to VISTA
- 作者：Chen Wenting;Qie Chenxin;Hu XinleiWang LanlanJiang JingweiLiu WanmeiLiu Jun
- 期刊名称：《Investigational new drugs.》 | 2022年第4期
- VSIG-8;
- VISTA;
- Cancer immunotherapy;
- Interaction;
- IMMUNE-CHECKPOINT;
- THERAPY;
23.Efficacy and safety of ramucirumab and docetaxel in previously treated patients with squamous cell lung cancer: a multicenter retrospective cohort study

机译：Efficacy and safety of ramucirumab and docetaxel in previously treated patients with squamous cell lung cancer: a multicenter retrospective cohort study
- 作者：Kawachi Hayato;Tamiya Motohiro;Matsumoto KinnosukeTamiya AkihiroYanase TakafumiTanizaki SatoshiKumagai Toru
- 期刊名称：《Investigational new drugs.》 | 2022年第3期
- Ramucirumab;
- Non-small cell lung cancer;
- Treatment outcome;
- Squamous cell carcinoma;
- RANDOMIZED PHASE-3;
- OPEN-LABEL;
- CHEMOTHERAPY;
- PEMBROLIZUMAB;
- ATEZOLIZUMAB;
- BEVACIZUMAB;
- CRITERIA;
24.Viscosalactone B, a natural LSD1 inhibitor, inhibits proliferation in vitro and in vivo against prostate cancer cells

机译：Viscosalactone B, a natural LSD1 inhibitor, inhibits proliferation in vitro and in vivo against prostate cancer cells
- 作者：Yan Gaobo;Zhang Hongyan;Li YanMiao GuoqiangLiu XiaoleiLv Qifan
- 期刊名称：《Investigational new drugs.》 | 2023年第1期
- LSD1;
- Viscosalactone B;
- Prostate cancer;
- MDV3100-resistant;
- WITHANIA-SOMNIFERA;
- CASTRATION-RESISTANT;
- CDK INHIBITORS;
25.ERK inhibitor ASN007 effectively overcomes acquired resistance to EGFR inhibitor in non-small cell lung cancer

机译：ERK inhibitor ASN007 effectively overcomes acquired resistance to EGFR inhibitor in non-small cell lung cancer
- 作者：Ku Bo Mi;Heo Jae Yeong;Kim JinchulSun Jong-MuLee Se-HoonAhn Jin SeokPark KeunchilAhn Myung-Ju
- 期刊名称：《Investigational new drugs.》 | 2022年第2期
- NSCLC;
- EGFR TKI;
- Acquired resistance;
- ERK inhibitor;
- Combination strategy;
- REACTIVATION;
- AZD9291;
26.The radiosensitizing effect of beta-Thujaplicin, a tropolone derivative inducing S-phase cell cycle arrest, in head and neck squamous cell carcinoma-derived cell lines

机译：The radiosensitizing effect of beta-Thujaplicin, a tropolone derivative inducing S-phase cell cycle arrest, in head and neck squamous cell carcinoma-derived cell lines
- 作者：Haas Markus;Lenz Teresa;Kadletz-Wanke LorenzHeiduschka GregorJank Bernhard J.
- 期刊名称：《Investigational new drugs.》 | 2022年第4期
- beta-Thujaplicin;
- Head and neck squamous cell carcinoma;
- cancer;
- HNSCC;
- Radiosensitization;
- CANCER-CELLS;
- HINOKITIOL;
- APOPTOSIS;
- DNA;
- EXPRESSION;
- MUTATIONS;
- INDUCTION;
- GROWTH;
- TP53;
27.The kinesin Eg5 inhibitor K858 exerts antiproliferative and proapoptotic effects and attenuates the invasive potential of head and neck squamous carcinoma cells

机译：The kinesin Eg5 inhibitor K858 exerts antiproliferative and proapoptotic effects and attenuates the invasive potential of head and neck squamous carcinoma cells
- 作者：Nicolai Alice;Taurone Samanta;Carradori SimoneArtico MarcoGreco AntonioCosti RobertaScarpa Susanna
- 期刊名称：《Investigational new drugs.》 | 2022年第3期
- Kinesin Eg5;
- K858;
- Head and neck cancer;
- Kinesin KIF11;
- CANCER;
- EXPRESSION;
- APOPTOSIS;
- MIGRATION;
- PHENOTYPE;
- PROTEIN;
28.Relation of overall tumor burden with severe immune-related adverse events in nivolumab plus ipilimumab treatment for lung cancer

机译：Relation of overall tumor burden with severe immune-related adverse events in nivolumab plus ipilimumab treatment for lung cancer
- 作者：Sumi Toshiyuki;Sekikawa Motoki;Nagahisa YutaMatsuura KeigoShijubou NaokiKamada KokiWatanabe HirokiYamada YuichiTanaka YusukeChiba Hirofumi
- 期刊名称：《Investigational new drugs.》 | 2022年第6期
- Immune-related adverse events;
- Non-small cell lung cancer;
- Tumor burden;
- Immune checkpoint inhibitors;
- Chemotherapy;
- CELL;
- THERAPY;
29.The efficacy and safety of immune checkpoint inhibitor plus chemotherapy in patients with advanced non-small-cell lung cancer: a meta-analysis

机译：The efficacy and safety of immune checkpoint inhibitor plus chemotherapy in patients with advanced non-small-cell lung cancer: a meta-analysis
- 作者：Meng Li-Fang;Huang Jian-Feng;Luo Peng-HuiHuang Shang-XiaoWang Han-Lei
- 期刊名称：《Investigational new drugs.》 | 2022年第4期
- Immune checkpoint inhibitor;
- PD-1;
- PD-L1;
- PD-L1 expression level;
- Efficacy and safety;
- Non-small-cell lung cancer;
- 1ST-LINE NIVOLUMAB;
- CARBOPLATIN;
- IPILIMUMAB;
- PACLITAXEL;
- ANTI-PD-1;
30.Bendamustine versus chlorambucil in treatment of chronic lymphocytic leukaemia in China: a randomized, open-label, parallel-controlled, phase III clinical trial

机译：Bendamustine versus chlorambucil in treatment of chronic lymphocytic leukaemia in China: a randomized, open-label, parallel-controlled, phase III clinical trial
- 作者：Zhou Daobin;Xu Wei;Ma HongbingZhao ChuntingHu YuZhao YaozhongWu DepeiZhao XielanHe YanjuanYan JinsongWang ChunsenMeng FanyiJin JieZhang XiaohongYu KangHu JiandaLv Yue
- 期刊名称：《Investigational new drugs.》 | 2022年第2期
31.Eftozanermin alfa (ABBV-621) monotherapy in patients with previously treated solid tumors: findings of a phase 1, first-in-human study

机译：Eftozanermin alfa (ABBV-621) monotherapy in patients with previously treated solid tumors: findings of a phase 1, first-in-human study
- 作者：LoRusso Patricia;Ratain Mark J.;Doi ToshihikoRasco Drew W.de Jonge Maja J. A.Moreno VictorCarneiro Benedito A.Devriese Lot A.Petrich AdamModi DimpleMorgan-Lappe SusanNuthalapati SilpaMotwani MonicaDunbar MartinGlasgow JaimeeMedeiros Bruno C.Calvo Emiliano
- 期刊名称：《Investigational new drugs.》 | 2022年第4期
- TRAIL-R agonist;
- Solid tumor;
- Dose-escalation;
- Dose-optimization;
- Phase 1;
- Apoptosis;
- ANTIBODY;
- CANCER;
- DS-8273A;
32.Selinexor synergizes with azacitidine to eliminate myelodysplastic syndrome cells through p53 nuclear accumulation

机译：Selinexor synergizes with azacitidine to eliminate myelodysplastic syndrome cells through p53 nuclear accumulation
- 作者：Guo Yixuan;Liu Zhaoyun;Duan LixiangShen HongliDing KaiFu Rong
- 期刊名称：《Investigational new drugs.》 | 2022年第4期
- Myelodysplastic syndromes;
- Azacitidine;
- Selinexor;
- P53;
- Apoptosis;
- SELECTIVE INHIBITORS;
- EXPORT;
- TRANSPORT;
- TARGET;
- CRM1;
33.Palladium(II) Schiff base complex arrests cell cycle at early stages, induces apoptosis, and reduces Ehrlich solid tumor burden: a new candidate for tumor therapy

机译：Palladium(II) Schiff base complex arrests cell cycle at early stages, induces apoptosis, and reduces Ehrlich solid tumor burden: a new candidate for tumor therapy
- 作者：Hassona Shahd M.;Saad Entsar A.;Kiwan Hala A.Hassanien Mohamed M.
- 期刊名称：《Investigational new drugs.》 | 2022年第4期
- Palladium;
- Platinum;
- Schiff base;
- Pd(II) complex;
- Cisplatin;
- Carcinoma;
- ASCITES-CARCINOMA;
- CANCER-CELLS;
- ANTITUMOR;
34.First-in-human trial exploring safety, antitumor activity, and pharmacokinetics of Sym013, a recombinant pan-HER antibody mixture, in advanced epithelial malignancies

机译：First-in-human trial exploring safety, antitumor activity, and pharmacokinetics of Sym013, a recombinant pan-HER antibody mixture, in advanced epithelial malignancies
- 作者：Berlin Jordan;Tolcher Anthony W.;Ding CliffWhisenant Jennifer G.Horak Ivan D.Wood Debra L.Nadler Paul IHansen Ulla HolmLantto JohanSkartved Niels Jorgen O.Pedersen Mikkel W.Patnaik Amita
- 期刊名称：《Investigational new drugs.》 | 2022年第3期
- Solid tumors;
- Novel drug;
- HER1;
- HER2;
- HER3;
- Monoclonal antibody;
- TARGETING EGFR;
- ERBB RECEPTORS;
- SOLID TUMORS;
- DACOMITINIB;
- INHIBITION;
- RESISTANCE;
- LAPATINIB;
- BLOCKADE;
- THERAPY;
- FAMILY;
35.First-line osimertinib for poor performance status patients with EGFR mutation-positive non-small cell lung cancer: A prospective observational study

机译：First-line osimertinib for poor performance status patients with EGFR mutation-positive non-small cell lung cancer: A prospective observational study
- 作者：Igawa Satoshi;Fukui Tomoya;Kasajima MasashiOno TaiheiOzawa TakahiroKakegawa MikikoKusuhara SeiichiroSato TakashiNakahara YoshiroHisashi MitsufujiSasaki JiichiroNaoki Katsuhiko
- 期刊名称：《Investigational new drugs.》 | 2022年第2期
- Non-small cell lung carcinoma;
- Poor performance status;
- Osimertinib;
- Efficacy;
- OPEN-LABEL;
- CHEMOTHERAPY;
- GEFITINIB;
- MULTICENTER;
- STATISTICS;
- ERLOTINIB;
- AFATINIB;
- NSCLC;
36.Long-term survival data of patients with limited disease small cell lung cancer: a retrospective analysis

机译：Long-term survival data of patients with limited disease small cell lung cancer: a retrospective analysis
- 作者：Doshita Kosei;Kenmotsu Hirotsugu;Omori ShotaTabuchi YuyaKawabata TakanoriKodama HiroakiNishioka NaoyaMiyawaki ErikoIida YukoMiyawaki TaichiMamesaya NobuakiKobayashi HarukiKo RyoWakuda KazushigeOno AkiraNaito TateakiMurakami HaruyasuMori KeitaHarada HideyukiKaneko TakeshiTakahashi Toshiaki
- 期刊名称：《Investigational new drugs.》 | 2022年第2期
- Chemoradiotherapy;
- Prognosis;
- Progression-free survival;
- Small cell lung cancer;
- Survival rate;
- THORACIC RADIOTHERAPY;
- PROGNOSTIC-FACTOR;
- CHEST RADIOTHERAPY;
- TUMOR VOLUME;
- STAGE;
- CONCURRENT;
- METAANALYSIS;
- CISPLATIN;
- ETOPOSIDE;
- CHEMORADIOTHERAPY;
37.The 45-month therapy outcomes of permanent seed implantation and radical prostatectomy for prostate cancer patients

机译：The 45-month therapy outcomes of permanent seed implantation and radical prostatectomy for prostate cancer patients
- 作者：Li Chao;Zhang Mengdong;Wang JianwenZhang Xiaodong
- 期刊名称：《Investigational new drugs.》 | 2022年第3期
- Permanent seed implantation;
- Radical prostatectomy;
- Survival rate;
- Security;
- Efficacy;
- I-125 SEEDS;
- BRACHYTHERAPY;
38.Orelabrutinib-bruton tyrosine kinase inhibitor-based regimens in the treatment of central nervous system lymphoma: a retrospective study

机译：Orelabrutinib-bruton tyrosine kinase inhibitor-based regimens in the treatment of central nervous system lymphoma: a retrospective study
- 作者：Wu Jing-Jing;Wang Wen-Hua;Dong MengMa Shan-ShanZhang Xu-DongZhu Li-NanNiu Song-TaoDing Meng-JieZhang Jie-MingZhang LeiLi XinLi LingSun Zhen-ChangWang Xin-HuaFu Xiao-RuiLi Zhao-MingChang YuNan Fei-FeiYan Jia-QinYu HuiWu Xiao-LongZhou Zhi-YuanZhang Ming-Zhi
- 期刊名称：《Investigational new drugs.》 | 2022年第3期
- Bruton tyrosine kinase;
- Central nervous system lymphoma;
- Prognosis;
- Orelabrutinib;
- PRIMARY CNS LYMPHOMA;
- IBRUTINIB MONOTHERAPY;
- DIAGNOSIS;
- METHOTREXATE;
39.Mesenchymal stem cells: a trojan horse to treat glioblastoma

机译：Mesenchymal stem cells: a trojan horse to treat glioblastoma
- 作者：AntoineChartouni;AntoineMouawad;MarcBoutrosFouadAttiehNicolasMedawarHampig Rapha?lKourie
- 期刊名称：《Investigational new drugs.》 | 2023年第2期
- Mesenchymal stem cells;
- Glioblastoma multiforme;
- Migration;
- Drug delivery vehicle;
- Cancer treatment;
40.A phase I/II study of MCS110 with BRAF/MEK inhibition in patients with melanoma after progression on BRAF/MEK inhibition

机译：A phase I/II study of MCS110 with BRAF/MEK inhibition in patients with melanoma after progression on BRAF/MEK inhibition
- 作者：Buchbinder Elizabeth I. I.;Giobbie-Hurder Anita;Ott Patrick A. A.
- 期刊名称：《Investigational new drugs.》 | 2023年第3期
- Melanoma;
- CSF1R inhibition;
- BRAF inhibition;
- MEK inhibition;
- COLONY-STIMULATING FACTOR;
- TUMOR-ASSOCIATED MACROPHAGES;
- BREAST CARCINOMAS;
- RECEPTOR;
- CSF-1;
- EXPRESSION;
- SURVIVAL;
- VEMURAFENIB;
- RESISTANCE;
- PROTEIN;
41.RNA silencing of GM-CSF in CAR-T cells reduces the secretion of multiple inflammatory cytokines

机译：RNA silencing of GM-CSF in CAR-T cells reduces the secretion of multiple inflammatory cytokines
- 作者：SiqiShang;YunshuoChen;XuejiaoYangYingYangWenboWangYueyingWang
- 期刊名称：《Investigational new drugs.》 | 2023年第2期
- Chimeric antigen receptor T cells;
- RNA silencing;
- Cytokine release syndrome;
- GM-CSF;
42.Phase I study of lurbinectedin in combination with weekly paclitaxel with or without bevacizumab in patients with advanced solid tumors

机译：Phase I study of lurbinectedin in combination with weekly paclitaxel with or without bevacizumab in patients with advanced solid tumors
- 作者：Calvo Emiliano;Sessa Cristiana;Harada Guilhermede Miguel MariaKahatt CarmenLuepke-Estefan Xarles ErikSiguero MarianoFernandez-Teruel CarlosCullell-Young MartinStathis AnastasiosDrilon Alexander
- 期刊名称：《Investigational new drugs.》 | 2022年第6期
- Lurbinectedin;
- Paclitaxel;
- Bevacizumab;
- Phase I study;
- CELL LUNG-CANCER;
- OVARIAN-CANCER;
- OPEN-LABEL;
- ONCOLOGY-GROUP;
- III TRIAL;
- 2ND-LINE TREATMENT;
- RANDOMIZED-TRIAL;
- DOUBLE-BLIND;
- RECURRENT;
- MULTICENTER;
43.DGG-300273, a novel WNT/beta-catenin inhibitor, induces apoptotic cell death by activating ROS-BIM signaling in a Wnt-dependent manner in colon cancer cells

机译：DGG-300273, a novel WNT/beta-catenin inhibitor, induces apoptotic cell death by activating ROS-BIM signaling in a Wnt-dependent manner in colon cancer cells
- 作者：Kim Do Yeon;Ryu Yea Seong;Lee Eun-SilKoh Dong-InMoon Jai-HeeJung Soo-AKim Mi JinYun HyeseonYou Ji-EunJeong Hong-RaeYoon Dong-IlKim Chul HeeHong Seung-WooGong Young-DaeJin Dong-Hoon
- 期刊名称：《Investigational new drugs.》 | 2023年第1期
- Bim;
- Colon cancer;
- DGG-300273;
- Reactive oxygen species (ROS);
- WNT;
- beta-catenin inhibitor;
- BETA-CATENIN;
- GROWTH;
- EXPRESSION;
44.FX1, a BCL6 inhibitor, reactivates BCL6 target genes and suppresses HTLV-1-infected T cells

机译：FX1, a BCL6 inhibitor, reactivates BCL6 target genes and suppresses HTLV-1-infected T cells
- 作者：Ishikawa Chie;Mori Naoki
- 期刊名称：《Investigational new drugs.》 | 2022年第2期
- Adult T cell leukemia;
- Human T cell leukemia virus type 1;
- BCL6;
- p53;
- NF-kappa B;
- Akt;
- NF-KAPPA-B;
- VIRUS TYPE-I;
- MONOCLONAL-ANTIBODY;
- CANCER;
- EXPRESSION;
- LEUKOCYTES;
- PARTICLES;
- MOLECULES;
- PATHWAY;
- LINES;
45.Effects of Nivolumab and Ipilimumab on the suppression of cisplatin resistant small cell lung cancer cells

机译：Effects of Nivolumab and Ipilimumab on the suppression of cisplatin resistant small cell lung cancer cells
- 作者：Chi Wei;Zhang Lianyong;Wang XueLi JingjingLi FeiMa YuxiaZhang Qianyun
- 期刊名称：《Investigational new drugs.》 | 2022年第4期
- Small cell lung cancer;
- Cisplatin;
- Nivolumab;
- Ipilimumab;
- PD-1;
- TUMOR-INFILTRATING LYMPHOCYTES;
- MULTICENTER PHASE-2;
- 1ST-LINE TREATMENT;
- DOUBLE-BLIND;
- CARBOPLATIN;
- STAGE;
- COMBINATION;
- PACLITAXEL;
- PROGNOSIS;
- THERAPY;
46.Boron neutron capture therapy using dodecaborated albumin conjugates with maleimide is effective in a rat glioma model

机译：Boron neutron capture therapy using dodecaborated albumin conjugates with maleimide is effective in a rat glioma model
- 作者：Kashiwagi Hideki;Kawabata Shinji;Yoshimura KoheiFukuo YusukeKanemitsu TakuyaTakeuchi KojiHiramatsu RyoNishimura KaiKawai KazukiTakata TakushiTanaka HirokiWatanabe TsubasaSuzuki MinoruMiyatake Shin-IchiNakamura HiroyukiWanibuchi Masahiko
- 期刊名称：《Investigational new drugs.》 | 2022年第2期
- Albumin;
- Boron neutron capture therapy;
- Dodecaborate;
- Drug delivery system;
- Maleimide;
- High-grade glioma;
- GLIOBLASTOMA-MULTIFORME;
- RECURRENT HEAD;
- PHASE-II;
- DELIVERY;
- TUMOR;
- RADIOTHERAPY;
47.Ketamine promotes breast tumor growth in a mouse breast tumor model involving with high expression of miR-27b-3p and EGFR

机译：Ketamine promotes breast tumor growth in a mouse breast tumor model involving with high expression of miR-27b-3p and EGFR
- 作者：Chen Li-Kuei;Shih Chien-Hung;Chen Shiou-ShengHuang Zi-XuanChang Yu-JungChen LinyiChuang Tsung-HsienChen Kuen-Bao
- 期刊名称：《Investigational new drugs.》 | 2022年第6期
- Ketamine;
- Breast cancer biomarker;
- Epidermal growth factor receptor;
- miR-27b-3p;
- APOPTOSIS;
- SUPPRESSION;
- METASTASES;
48.Analysis of melanoma tumor antigens and immune subtypes for the development of mRNA vaccine (Aug, 10.1007/s10637-022-01290-y, 2022)

机译：Analysis of melanoma tumor antigens and immune subtypes for the development of mRNA vaccine (Aug, 10.1007/s10637-022-01290-y, 2022)
- 作者：Ping Haiqin;Yu Wenjun;Gong XiaomingTong XinLin CheyuChen ZhaojunCai CaiyunGuo KaiKe Hengning
- 期刊名称：《Investigational new drugs.》 | 2022年第6期
49.Phase 1 study to determine the safety and dosing of autologous PBMCs modified to present HPV16 antigens (SQZ-PBMC-HPV) in HLA-A*02+ patients with HPV16+ solid tumors

机译：Phase 1 study to determine the safety and dosing of autologous PBMCs modified to present HPV16 antigens (SQZ-PBMC-HPV) in HLA-A*02+ patients with HPV16+ solid tumors
- 作者：AntonioJimeno;JoaquinaBaranda;Wade T.IamsJong ChulParkMonicaMitaMichael S.GordonMatthewTaylorNeeshaDhaniAlexis D.LealPrakashNeupaneCathyEngOladapoYekuAlainMitaJustin C.MoserMarcusButlerScott M.LoughheadJuliaJenningsNathan R.MiselisRui-RuJiNityaNairMartinKornackerRicardo F.ZwirtesHowardBernsteinArmonSharei
- 期刊名称：《Investigational new drugs.》 | 2023年第2期
- Cellular therapy;
- HPV16;
- Antigen presenting cell;
- Immunotherapy;
- Cancer vaccine;
50.A prospective multicenter phase II study of FOLFIRINOX as a first-line treatment for patients with advanced and recurrent biliary tract cancer

机译：A prospective multicenter phase II study of FOLFIRINOX as a first-line treatment for patients with advanced and recurrent biliary tract cancer
- 作者：Takahara Naminatsu;Nakai Yousuke;Isayama HiroyukiSasaki TakashiMorine YujiWatanabe KazuoUeno MakotoIoka TatsuyaKanai MasashiKondo ShunsukeOkano NaohiroKoike Kazuhiko
- 期刊名称：《Investigational new drugs.》 | 2023年第1期
- Antineoplastic agents;
- Biliary tract neoplasms;
- Cholangiocarcinoma;
- chemotherapy;
- FOLFIRINOX;
- OPEN-LABEL;
- PRECISION MEDICINE;
- PLUS S-1;
- GEMCITABINE;
- CISPLATIN;
- CHEMOTHERAPY;
- COMBINATION;
- CHOLANGIOCARCINOMA;
- OXALIPLATIN;
- EFFICACY;
51.A novel SLC8A1/LINC01913 intergenic region-ALK fusion identified by NGS and validated by IHC and FISH in a stage IIB lung adenocarcinoma patient who remains relapse-free during the treatment of crizotinib: A case report (Aug, 10.1007/s10637-022-01262-2, 2022)

机译：A novel SLC8A1/LINC01913 intergenic region-ALK fusion identified by NGS and validated by IHC and FISH in a stage IIB lung adenocarcinoma patient who remains relapse-free during the treatment of crizotinib: A case report (Aug, 10.1007/s10637-022-01262-2, 2022)
- 作者：Wang Chunguang;Chen Shu;He QianruSun TingtingXu Peiran
- 期刊名称：《Investigational new drugs.》 | 2022年第6期
52.A tumor-selective adenoviral vector platform induces transient antiphospholipid antibodies, without increased risk of thrombosis, in phase 1 clinical studies

机译：A tumor-selective adenoviral vector platform induces transient antiphospholipid antibodies, without increased risk of thrombosis, in phase 1 clinical studies
- 作者：Danny N.Khalil;IsabelPrieto González-Albo;LeeRosenTomLillieAndreaStaceyLolaParfittGerald A.Soff
- 期刊名称：《Investigational new drugs.》 | 2023年第2期
- Activated partial thromboplastin time;
- Adenoviral vector;
- Antiphospholipid antibody;
- Clinical study;
- Safety;
53.Two novel piperidones induce apoptosis and antiproliferative effects on human prostate and lymphoma cancer cell lines

机译：Two novel piperidones induce apoptosis and antiproliferative effects on human prostate and lymphoma cancer cell lines
- 作者：Swain Risa Mia;Contreras Lisett;Varela-Ramirez ArmandoHossain MohammadDas UmashankarValenzuela Carlos A.Penichet Manuel L.Dimmock Jonathan R.Aguilera Renato J.
- 期刊名称：《Investigational new drugs.》 | 2022年第5期
- Colorectal Cancer;
- Hematopoietic malignancies;
- Cytotoxicity;
- Piperidones;
- Apoptosis;
- Anticancer;
- Dichloroacetate;
- PROTEASOME;
- DERIVATIVES;
- ACTIVATION;
- INHIBITORS;
- PATHWAYS;
54.Phase II study of dichloroacetate, an inhibitor of pyruvate dehydrogenase, in combination with chemoradiotherapy for unresected, locally advanced head and neck squamous cell carcinoma

机译：Phase II study of dichloroacetate, an inhibitor of pyruvate dehydrogenase, in combination with chemoradiotherapy for unresected, locally advanced head and neck squamous cell carcinoma
- 作者：Powell Steven F.;Mazurczak Miroslaw;Dib Elie G.Bleeker Jonathon S.Geeraerts Louis H.Tinguely MatthewLohr Michele M.McGraw Steven C.Jensen Ashley W.Ellison Christie A.Black Lora J.Puumala Susan E.Reed Valerie J.Miskimins W. KeithLee John H.Spanos William C.
- 期刊名称：《Investigational new drugs.》 | 2022年第3期
- Dichloroacetate;
- Chemoradiotherapy;
- Head and neck cancer;
- Tumor microenvironment;
- LACTIC-ACID;
- HUMAN-PAPILLOMAVIRUS;
- THERAPY;
- LACTATE;
- SURVIVAL;
- DCA;
- OROPHARYNGEAL;
- CRITERIA;
- TUMORS;
- TRIAL;
55.Anti-cancer activity of ultra-short single-stranded polydeoxyribonucleotides

机译：Anti-cancer activity of ultra-short single-stranded polydeoxyribonucleotides
- 作者：Vedenkin Alexander S.;Stovbun Sergey V.;Bukhvostov Alexander A.Zlenko Dmitry V.Stovbun Ivan S.Silnikov Vladimir N.Fursov Valentin V.Kuznetsov Dmitry A.
- 期刊名称：《Investigational new drugs.》 | 2023年第1期
- Single-stranded DNA;
- DNA repair;
- Cancer;
- cytostatics;
- DNA-POLYMERASE BETA;
- REPLICATION STRESS;
- INHIBITION;
- MECHANISM;
- LEUKEMIA;
56.Complete Response to tenalisib and romidepsin with long-term maintenance using tenalisib monotherapy in a patient with relapsed and refractory sézary syndrome

机译：Complete Response to tenalisib and romidepsin with long-term maintenance using tenalisib monotherapy in a patient with relapsed and refractory sézary syndrome
- 作者：Christopher N.Nguyen;Swaminathan P.Iyer;MadeleineDuvicPrajak J.BardeAjitNairKasi ViswanathRouthuAuris O.Huen
- 期刊名称：《Investigational new drugs.》 | 2023年第2期
- Cutaneous T Cell Lymphoma;
- Sézary Syndrome;
- Mycosis Fungoides;
- Refractory;
57.Selinexor in combination with topotecan in patients with advanced or metastatic solid tumors: Results of an open-label, single-center, multi-arm phase Ib study (vol 39, pg 1357, 2021)

机译：Selinexor in combination with topotecan in patients with advanced or metastatic solid tumors: Results of an open-label, single-center, multi-arm phase Ib study (vol 39, pg 1357, 2021)
- 作者：Thein Kyaw Zin;Piha-Paul Sarina A.;Tsimberidou ApostoliaKarp Daniel D.Janku FilipZarifa AbdulrazzakShah JatinMilton Denai R.Bean StacieMcQuinn LaceyGong JingColen RivkaCarter Brett W.Subbiah VivekOgbonna Deby C.Pant ShubhamMeric-Bernstam FundaNaing Aung
- 期刊名称：《Investigational new drugs.》 | 2022年第2期
58.TRIM59 guards ER proteostasis and prevents Bortezomib-mediated colorectal cancer (CRC) cells' killing

机译：TRIM59 guards ER proteostasis and prevents Bortezomib-mediated colorectal cancer (CRC) cells' killing
- 作者：Feng Xuejia;Yang Gui;Zhang LitianTao ShishiShim Joong SupChen LiangWu Qingxia
- 期刊名称：《Investigational new drugs.》 | 2022年第6期
59.Abdominal pain accompanied by elevated serum inflammatory markers and biliary enzymes for diagnosing immune checkpoint inhibitor-induced sclerosing cholangitis

机译：Abdominal pain accompanied by elevated serum inflammatory markers and biliary enzymes for diagnosing immune checkpoint inhibitor-induced sclerosing cholangitis
- 作者：Yamamoto Takafumi;Mizuno Kazuyuki;Ito TakanoriYokoyama ShinyaYamamoto KentaImai NorihiroIshizu YojiHonda TakashiIshikawa TakuyaKanamori AkiraYasuda SatoshiToyoda HidenoriYokota KenjiHase TetsunariNishio NaokiMaeda OsamuIshii MakotoSone MichihikoAndo YuichiAkiyama MasashiIshigami MasatoshiKawashima Hiroki
- 期刊名称：《Investigational new drugs.》 | 2023年第3期
60.Oral formulation of bendamustine hydrochloride for patients with advanced solid tumors; a phase 1 study

机译：Oral formulation of bendamustine hydrochloride for patients with advanced solid tumors; a phase 1 study
- 作者：Shimizu Toshio;Nakagawa Kazuhiko;Hayashi HidetoshiIwasa TsutomuKawakami HisatoWatanabe SatomiYamamoto NoboruYonemori KanKoyama TakafumiSato JunTamura KenjiKikuchi KeiichiAkaike KenichiroTakeda ShihoTakeda Masayuki
- 期刊名称：《Investigational new drugs.》 | 2023年第1期
- Bendamustine;
- Oral formulation;
- Pharmacokinetics;
- Phase I study;
- Solid tumor;
- METASTATIC BREAST-CANCER;
- CHRONIC LYMPHOCYTIC-LEUKEMIA;
- 1ST-LINE TREATMENT;
- OPEN-LABEL;
- PLUS BENDAMUSTINE;
- II TRIAL;
- RITUXIMAB;
- INDOLENT;
- CHEMOTHERAPY;
- MULTICENTER;
61.Optimal threshold of alpha-fetoprotein response in patients with unresectable hepatocellular carcinoma treated with atezolizumab and bevacizumab

机译：Optimal threshold of alpha-fetoprotein response in patients with unresectable hepatocellular carcinoma treated with atezolizumab and bevacizumab
- 作者：Tamaki Nobuharu;Tada Toshifumi;Kurosaki MasayukiYasui YutakaOchi HironoriMashiba ToshieSakamoto AzusaMarusawa HiroyukiNarita RyoichiUchida YasushiAkahane TakehiroKondo MasahikoMori NamiTakaki ShintaroTsuji KeijiKobashi HaruhikoKusakabe AtsunoriFuruta KoichiroArai HirotakaNonogi MichikoOgawa ChikaraSato TakashiTamada TakashiNakamura ShinichiroHasebe ChitomiTsuchiya KaoruIzumi Namiki
- 期刊名称：《Investigational new drugs.》 | 2022年第6期
- Hepatocellular carcinoma (HCC);
- Atezolizumab;
- Bevacizumab;
- Alpha-fetoprotein (AFP);
- 1ST-LINE TREATMENT;
- PLUS BEVACIZUMAB;
- LENVATINIB;
- SORAFENIB;
- OUTCOMES;
- THERAPY;
62.Carbidopa suppresses estrogen receptor-positive breast cancer via AhR-mediated proteasomal degradation of ER alpha

机译：Carbidopa suppresses estrogen receptor-positive breast cancer via AhR-mediated proteasomal degradation of ER alpha
- 作者：Chen Zhiwei;Xia Xing;Chen HeyanHuang HuirongAn XingsiSun MengYao QingKim KwonseopZhang HailinChu MaopingChen RuijieBhutia Yangzom D.Ganapathy VadivelKou Longfa
- 期刊名称：《Investigational new drugs.》 | 2022年第6期
- Carbidopa;
- Estrogen receptor-positive breast cancer;
- AhR;
- Proteasomal degradation;
- ER alpha;
- ARYL-HYDROCARBON RECEPTOR;
- PARKINSONS-DISEASE;
- CARCINOGENESIS;
- LEVODOPA;
- DOCKING;
- DIOXIN;
63.Phase I trial of ATM inhibitor M3541 in combination with palliative radiotherapy in patients with solid tumors (Feb, 10.1007/s10637-022-01216-8, 2022)

机译：Phase I trial of ATM inhibitor M3541 in combination with palliative radiotherapy in patients with solid tumors (Feb, 10.1007/s10637-022-01216-8, 2022)
- 作者：Waqar Saiama N.;Robinson Clifford;Olszanski Anthony J.Spira AlexanderHackmaster MelissaLucas LuisaSponton LauraJin HulinHering UrsulaCronier DamienGrinberg MariannaSeithel-Keuth AnnickDiaz-Padilla IvanBerlin Jordan
- 期刊名称：《Investigational new drugs.》 | 2022年第3期
64.Phase Ia dose escalation study of OBP-801, a cyclic depsipeptide class I histone deacetylase inhibitor, in patients with advanced solid tumors

机译：Phase Ia dose escalation study of OBP-801, a cyclic depsipeptide class I histone deacetylase inhibitor, in patients with advanced solid tumors
- 作者：Heath Elisabeth I.;Weise Amy;Vaishampayan UlkaDanforth DailanUngerleider Richard S.Urata Yasuo
- 期刊名称：《Investigational new drugs.》 | 2022年第2期
- Histone deacetylase inhibitors;
- OBP-801;
- Phase Ia;
- Solid tumors;
- ACETYLATION;
65.Population Pharmacokinetics, Pharmacogenomics, and Adverse Events of Osimertinib and its Two Active Metabolites, AZ5104 and AZ7550, in Japanese Patients with Advanced Non-small Cell Lung Cancer: a Prospective Observational Study

机译：Population Pharmacokinetics, Pharmacogenomics, and Adverse Events of Osimertinib and its Two Active Metabolites, AZ5104 and AZ7550, in Japanese Patients with Advanced Non-small Cell Lung Cancer: a Prospective Observational Study
- 作者：Ishikawa Emi;Yokoyama Yuta;Chishima HarunaKasai HidefumiKuniyoshi OukiKimura MotonoriHakamata JunNakada HideoSuehiro NaoyaNakaya NaokiNakajima HideoIkemura ShinnosukeKawada IchiroYasuda HiroyukiTerai HidekiJibiki AyaKawazoe HitoshiSoejima KenzoMuramatsu HiroshiSuzuki SayoNakamura Tomonori
- 期刊名称：《Investigational new drugs.》 | 2023年第1期
- Osimertinib;
- Active metabolites;
- Adverse events;
- Population pharmacokinetics;
- Pharmacogenomics;
- Therapeutic drug monitoring;
- GENETIC POLYMORPHISMS;
- GEFITINIB TOXICITY;
- EGFR;
- ENZYMES;
- ABCG2;
66.Blockade of Myd88 signaling by a novel MyD88 inhibitor prevents colitis-associated colorectal cancer development by impairing myeloid-derived suppressor cells

机译：Blockade of Myd88 signaling by a novel MyD88 inhibitor prevents colitis-associated colorectal cancer development by impairing myeloid-derived suppressor cells
- 作者：Wang Lu;Hu Dan;Xie BinXie Lin
- 期刊名称：《Investigational new drugs.》 | 2022年第3期
- MyD88 signaling;
- Myeloid-derived suppressor cells;
- Colitis-associated colorectal cancer;
- MyD88 inhibitor;
- IMMUNOTHERAPY;
- INFLAMMATION;
- TOLERANCE;
- IMMUNITY;
- SUBSETS;
67.Relapsing polychondritis after treatment with PD-1 blockade

机译：Relapsing polychondritis after treatment with PD-1 blockade
- 作者：Ogimoto Tatsuya;Yoshida Hironori;Mizuta MasanobuHirai Toyohiro
- 期刊名称：《Investigational new drugs.》 | 2022年第2期
- Relapsing polychondritis;
- Immune checkpoint inhibitor;
- Nivolumab;
- Immune-related adverse event;
68.Actively targeted delivery of SN38 by ultrafine iron oxide nanoparticle for treating pancreatic cancer

机译：Actively targeted delivery of SN38 by ultrafine iron oxide nanoparticle for treating pancreatic cancer
- 作者：Xue Ting;Xu Peijia;Padelford JonathanXue XingkuiWu Alyssa Y.Li YuanchengWang Liya
- 期刊名称：《Investigational new drugs.》 | 2022年第3期
69.Increased DKC1 expression in glioma and its significance in tumor cell proliferation, migration and invasion (vol 37, pg 1177, 2019)

机译：Increased DKC1 expression in glioma and its significance in tumor cell proliferation, migration and invasion (vol 37, pg 1177, 2019)
- 作者：Miao Fa-an;Chu Kun;Chen Hai-rongZhang MengShi Pei-congBai JinYou Yong-ping
- 期刊名称：《Investigational new drugs.》 | 2022年第3期
70.Efficacy of apatinib combined with FOLFIRI in the first-line treatment of patients with metastatic colorectal cancer

机译：Efficacy of apatinib combined with FOLFIRI in the first-line treatment of patients with metastatic colorectal cancer
- 作者：Rong Xuetong;Liu Haiyi;Yu HongmeiZhao JianWang JieWang Yusheng
- 期刊名称：《Investigational new drugs.》 | 2022年第2期
- Apatinib;
- FOLFIRI;
- Colorectal adenocarcinoma;
- Survival;
- AUTOPHAGY;
- CETUXIMAB;
- SURVIVAL;
71.Effects on survival of the adverse event of atezolizumab plus bevacizumab for hepatocellular carcinoma: a multicenter study by the Japan Red Cross Liver Study Group

机译：Effects on survival of the adverse event of atezolizumab plus bevacizumab for hepatocellular carcinoma: a multicenter study by the Japan Red Cross Liver Study Group
- 作者：ShintaroTakaki;MasayukiKurosaki;NamiMoriKeijiTsujiHironoriOchiHiroyukiMarusawaShinichiroNakamuraToshifumiTadaRyoichiNaritaYasushiUchidaTakehiroAkahaneMasahikoKondoAtsunoriKusakabeKoichiroFurutaHaruhikoKobashiHirotakaAraiMichikoNonogiTakashiTamadaChitomiHasebeChikaraOgawaTakashiSatoNobuharuTamakiYutakaYasuiKaoruTsuchiyaNamikiIzumi
- 期刊名称：《Investigational new drugs.》 | 2023年第2期
- Unresectable HCC;
- Proteinuria;
- Atezolizumab;
- Bevacizumab;
72.Phase I study to evaluate of the gastric pH-dependent drug interaction between famitinib and the proton pump inhibitor omeprazole in healthy subjects

机译：Phase I study to evaluate of the gastric pH-dependent drug interaction between famitinib and the proton pump inhibitor omeprazole in healthy subjects
- 作者：Hu Linlin;Cai Mingmin;Qian WeiDou TingSun QiuyueTang LuWang Huiping
- 期刊名称：《Investigational new drugs.》 | 2022年第6期
- Gastric pH-dependent drug interactions;
- Omeprazole;
- Pharmacokinetics;
- Famitinib;
- TYROSINE-KINASE;
- ANTITUMOR-ACTIVITY;
- PHARMACOKINETICS;
- RECEPTOR;
73.Phase I trial of ATM inhibitor M3541 in combination with palliative radiotherapy in patients with solid tumors

机译：Phase I trial of ATM inhibitor M3541 in combination with palliative radiotherapy in patients with solid tumors
- 作者：Waqar Saiama N.;Robinson Clifford;Olszanski Anthony J.Spira AlexanderHackmaster MelissaLucas LuisaSponton LauraJin HulinHering UrsulaCronier DamienGrinberg MariannaSeithel-Keuth AnnickDiaz-Padilla IvanBerlin Jordan
- 期刊名称：《Investigational new drugs.》 | 2022年第3期
- M3541;
- ATM inhibitor;
- Solid tumor;
- Palliative radiotherapy;
- DNA damage response;
- DNA repair;
74.Autoimmune hemolytic anemia in patients with relapsed Hodgkin's lymphoma after treatment with penpulimab, a monoclonal antibody against programmed death receptor-1

机译：Autoimmune hemolytic anemia in patients with relapsed Hodgkin's lymphoma after treatment with penpulimab, a monoclonal antibody against programmed death receptor-1
- 作者：Tao Yiming;Han Jie;Li Yongsheng
- 期刊名称：《Investigational new drugs.》 | 2022年第4期
- Hodgkin's lymphoma;
- Penpulimab;
- Autoimmune hemolytic anemia;
- Immune-related adverse events;
75.Dasatinib in combination with BMS-754807 induce synergistic cytotoxicity in lung cancer cells through inhibiting lung cancer cell growth, and inducing autophagy as well as cell cycle arrest at the G1 phase

机译：Dasatinib in combination with BMS-754807 induce synergistic cytotoxicity in lung cancer cells through inhibiting lung cancer cell growth, and inducing autophagy as well as cell cycle arrest at the G1 phase
- 作者：Zhang Chan;Zhao Xinan;Wang ZifengGong TaoZhao HongZhang DongNiu YuhuLi XiaoningZhao XuhuaLi GaopengDong XiushanZhang LiLiu ChangXu JunYu Baofeng
- 期刊名称：《Investigational new drugs.》 | 2023年第3期
- Dasatinib;
- BMS-754807;
- Drug combination;
- Lung cancer;
- Autophagy;
- INSULIN;
- PATHWAY;
76.Phenformin increases early hematopoietic progenitors in the Jak2(V617F) murine model

机译：Phenformin increases early hematopoietic progenitors in the Jak2(V617F) murine model
- 作者：Alves-Silva Antonio Bruno;Fenerich Bruna Alves;Fonseca Natasha PeixotoFernandes Jaqueline CristinaCoelho-Silva Juan LuizPereira-Martins Diego AntonioBianco Thiago MantelloScheucher Priscila SantosRego Eduardo MagalhaesChahud FernandoMachado-Neto Joao AgostinhoFigueiredo-Pontes Lorena LoboTraina Fabiola
- 期刊名称：《Investigational new drugs.》 | 2022年第3期
- Myeloproliferative neoplasms;
- Phenformin;
- JAK2;
- Polycythemia vera;
- Murine model;
- Biguanide;
- TYROSINE KINASE JAK2;
- METFORMIN;
- CELLS;
- BIGUANIDES;
- MUTATION;
- TRANSPORTER;
- THERAPY;
- GROWTH;
- AMPK;
77.A lung adenocarcinoma patient harboring MET c. 3028+2 T A variant sensitive to crizotinib treatment

机译：A lung adenocarcinoma patient harboring MET c. 3028+2 T A variant sensitive to crizotinib treatment
- 作者：Jiang Rui;Wei Dongguang;Tan YuanDuan Qianqian
- 期刊名称：《Investigational new drugs.》 | 2022年第4期
- NGS;
- Lung adenocarcinoma;
- MET 14 skipping;
- IHC;
- qPCR;
78.Necitumumab plus gemcitabine and cisplatin in previously treated lung squamous cell carcinoma

机译：Necitumumab plus gemcitabine and cisplatin in previously treated lung squamous cell carcinoma
- 作者：Kinoshita Fumihiko;Oku Yuka;Takamori ShinkichiFujishita TakatoshiToyozawa RyoIto KensakuShoji FumihiroOkamoto Tatsuro
- 期刊名称：《Investigational new drugs.》 | 2023年第1期
- Lung cancer;
- Squamous cell carcinoma;
- Necitumumab;
- Chemotherapy;
- OPEN-LABEL;
- CHEMOTHERAPY;
- CANCER;
- PEMBROLIZUMAB;
- CRIZOTINIB;
- TRIAL;
79.A tumor-selective adenoviral vector platform induces transient antiphospholipid antibodies, without increased risk of thrombosis, in phase 1 clinical studies (vol 41, pg 317,2023)

机译：A tumor-selective adenoviral vector platform induces transient antiphospholipid antibodies, without increased risk of thrombosis, in phase 1 clinical studies (vol 41, pg 317,2023)
- 作者：Khalil Danny N.;Gonzalez-Albo Isabel Prieto;Rosen LeeLillie TomStacey AndreaParfitt LolaSoff Gerald A.
- 期刊名称：《Investigational new drugs.》 | 2023年第3期
80.Initial and supplementary indication approval of new targeted cancer drugs by the FDA, EMA, Health Canada, and TGA

机译：Initial and supplementary indication approval of new targeted cancer drugs by the FDA, EMA, Health Canada, and TGA
- 作者：Michaeli Daniel Tobias;Mills Mackenzie;Michaeli ThomasMiracolo AurelioKanavos Panos
- 期刊名称：《Investigational new drugs.》 | 2022年第4期
- Cancer drugs;
- Targeted therapy;
- Orphan;
- Accelerated approval;
- Drug development;
- Clinical trial;
- Drug pricing;
- Pharmaceutical policy;
- Indication-specific pricing;
- ORPHAN DRUGS;
- PHARMACEUTICALS;
- US;
81.Combination of ruxolitinib with ABT-737 exhibits synergistic effects in cells carrying concurrent JAK2(V617F) and ASXL1 mutations

机译：Combination of ruxolitinib with ABT-737 exhibits synergistic effects in cells carrying concurrent JAK2(V617F) and ASXL1 mutations
- 作者：Yuan Jiajia;Song Junzhe;Chen ChaoLv XueBai JieYang JingZhou Yuan
- 期刊名称：《Investigational new drugs.》 | 2022年第6期
- Ruxolitinib;
- BCL2 inhibitor;
- MPN;
- Apoptosis;
- TYROSINE KINASE JAK2;
- MYELOPROLIFERATIVE NEOPLASMS;
- HEMATOPOIETIC STEM;
- MIMETIC ABT-737;
- RESISTANCE;
- BCL-2;
- TRANSFORMATION;
- SENSITIVITY;
- ACTIVATION;
- MECHANISMS;
82.Leukotriene B4 receptor 2 correlates with prognosis and immune infiltration in clear cell renal cell carcinoma

机译：Leukotriene B4 receptor 2 correlates with prognosis and immune infiltration in clear cell renal cell carcinoma
- 作者：Yuan Xia;He Yi;Luo ChenhuiWang Wei
- 期刊名称：《Investigational new drugs.》 | 2022年第2期
- BLT2 expression;
- Clear cell renal cell carcinoma;
- Prognosis;
- Immune infiltration;
- CANCER;
- SUNITINIB;
- HYPOXIA;
- BLT2;
83.Pharmacokinetics and bioequivalence of two pomalidomide capsules in healthy chinese subjects under fasting and fed conditions

机译：Pharmacokinetics and bioequivalence of two pomalidomide capsules in healthy chinese subjects under fasting and fed conditions
- 作者：Liu Zhengzhi;Xu Zhongnan;Gao ZhenyueRen QingChang TianyingXue JinlingYang Haimiao
- 期刊名称：《Investigational new drugs.》 | 2023年第1期
- Bioequivalence;
- Multiple myeloma;
- Pomalidomide;
- Safety;
- Pharmacokinetics;
- MULTIPLE-MYELOMA;
- SIMILARITIES;
- THALIDOMIDE;
- MECHANISMS;
- CELLS;
84.Prospective role of liquid biopsy for early screening in laryngeal cancer

机译：Prospective role of liquid biopsy for early screening in laryngeal cancer
- 作者：Gong Xiao-yang;Chen Hai-bing;Lu Zhao-yiZhu ChanChen Dong-shengChen Xi
- 期刊名称：《Investigational new drugs.》 | 2023年第3期
- BIOMARKERS;
85.A novel SLC8A1/LINC01913 intergenic region-ALK fusion identified by NGS and validated by IHC and FISH in a stage IIB lung adenocarcinoma patient who remains relapse-free during the treatment of crizotinib: a case report

机译：A novel SLC8A1/LINC01913 intergenic region-ALK fusion identified by NGS and validated by IHC and FISH in a stage IIB lung adenocarcinoma patient who remains relapse-free during the treatment of crizotinib: a case report
- 作者：Wang Chunguang;Chen Shu;He QianruSun TingtingXu Peiran
- 期刊名称：《Investigational new drugs.》 | 2022年第6期
- Lung cancer;
- Intergenic region ALK Fusion;
- Adjuvant crizotinib;
- OUTCOMES;
86.A phase Ib study of adavosertib, a selective Wee1 inhibitor, in patients with locally advanced or metastatic solid tumors

机译：A phase Ib study of adavosertib, a selective Wee1 inhibitor, in patients with locally advanced or metastatic solid tumors
- 作者：Falchook Gerald S.;Sachdev Jasgit;Imedio Esteban RodrigoKumar SanjeevMugundu Ganesh M.Jenkins SuzanneChmielecki JuliannJones SuzanneSpigel David R.Johnson Melissa
- 期刊名称：《Investigational new drugs.》 | 2023年第3期
- Adavosertib;
- AZD1775;
- Cancer;
- Wee1;
- Clinical trial;
- Phase I;
- MK-1775;
- KINASE;
- REPLICATION;
- GEMCITABINE;
- COMBINATION;
- AGENTS;
87.The addition of the immunomodulator mifamurtide to adjuvant chemotherapy for early osteosarcoma: a retrospective analysis

机译：The addition of the immunomodulator mifamurtide to adjuvant chemotherapy for early osteosarcoma: a retrospective analysis
- 作者：Kokkali Stefania;Kotsantis Ioannis;Magou ElpidaSophia TalaganiKormas TheodorosDiakoumis GiakoumisSpathas NikolaosPsyrri AmandaArdavanis Alexandros
- 期刊名称：《Investigational new drugs.》 | 2022年第3期
88.A pharmacokinetic study to comparatively evaluate the bioequivalence and safety of a humanized recombinant monoclonal antibody targeting human epidermal growth factor receptor-2 with the reference Herceptin in healthy Chinese subjects

机译：A pharmacokinetic study to comparatively evaluate the bioequivalence and safety of a humanized recombinant monoclonal antibody targeting human epidermal growth factor receptor-2 with the reference Herceptin in healthy Chinese subjects
- 作者：Ding Fangfang;Huang Jie;Feng ZeyingKuang YunYang ShuangXiang YuxiaZou ChanYang Guoping
- 期刊名称：《Investigational new drugs.》 | 2022年第3期
- Bioequivalence;
- Herceptin;
- Pharmacokinetic;
- Safety;
- METASTATIC BREAST-CANCER;
- TRASTUZUMAB;
- TRIAL;
89.In vitro effects of gamma-secretase inhibition in HPV-positive and HPV-negative head and neck squamous cell carcinoma

机译：In vitro effects of gamma-secretase inhibition in HPV-positive and HPV-negative head and neck squamous cell carcinoma
- 作者：SaraVaratanovic;TobiasMaier;SegaAl-GbooreStefanStoiberSam AugustineKandathilClemensQuintCharlotteBrennusGregorHeiduschkaLorenzKadletz-WankeFaris F.Brkic
- 期刊名称：《Investigational new drugs.》 | 2023年第2期
- Head and neck squamous cell carcinoma;
- Notch pathway;
- Gamma-secretase inhibitor;
90.Toxicity profile of anaplastic lymphoma kinase tyrosine kinase inhibitors for patients with non-small cell lung cancer: A systematic review and meta-analysis

机译：Toxicity profile of anaplastic lymphoma kinase tyrosine kinase inhibitors for patients with non-small cell lung cancer: A systematic review and meta-analysis
- 作者：Tao Yunxia;Zhou Yu;Tang LeChen HaizhuFeng YuShi Yuankai
- 期刊名称：《Investigational new drugs.》 | 2022年第4期
- Anaplastic lymphoma kinase tyrosine kinase inhibitors;
- Adverse events;
- Non-small cell lung cancer;
- Meta-analysis;
- OPEN-LABEL;
- PHASE 1/2;
- CRIZOTINIB;
- CERITINIB;
- CHEMOTHERAPY;
- SURVIVAL;
- SAFETY;
- MULTICENTER;
91.Novel pentacyclic derivatives and benzylidenes of the progesterone series cause anti-estrogenic and antiproliferative effects and induce apoptosis in breast cancer cells

机译：Novel pentacyclic derivatives and benzylidenes of the progesterone series cause anti-estrogenic and antiproliferative effects and induce apoptosis in breast cancer cells
- 作者：Scherbakov Alexander M.;Vorontsova Svetlana K.;Khamidullina Alvina IMrdjanovic JasminkaAndreeva Olga E.Bogdanov Fedor B.Salnikova Diana I.Jurisic VladimirZavarzin Igor V.Shirinian Valerii Z.
- 期刊名称：《Investigational new drugs.》 | 2023年第1期
- Antiestrogenic activity;
- Benzylidenes;
- Breast cancer;
- Estrogen receptor alpha;
- Pentacyclic steroids;
- TAMOXIFEN ICI 46;
- 474;
- AROMATASE INHIBITORS;
- ESTROGEN-RECEPTOR;
- CARCINOMA;
- ARREST;
- G2/M;
- ACTIVATION;
- THERAPY;
- ALPHA;
- MCF-7;
92.Practical consideration for successful sequential tumor biopsies in first-in-human trials

机译：Practical consideration for successful sequential tumor biopsies in first-in-human trials
- 作者：Koyama Takafumi;Shimizu Toshio;Sato JunKatsuya YukiIwasa SatoruKondo ShunsukeYoshida TatsuyaSudo KazukiNishino MakotoTakiguchi YuichiYonemori KanYamamoto Noboru
- 期刊名称：《Investigational new drugs.》 | 2022年第4期
- Biopsy;
- Clinical Trial;
- Disease Progression;
- Diagnostic Imaging;
- Therapeutics;
- AE;
- CLINICAL-TRIALS;
- CANCER;
- FEASIBILITY;
93.A phase 1 study to assess the safety, pharmacokinetics, and anti-tumor activity of the androgen receptor n-terminal domain inhibitor epi-506 in patients with metastatic castration-resistant prostate cancer

机译：A phase 1 study to assess the safety, pharmacokinetics, and anti-tumor activity of the androgen receptor n-terminal domain inhibitor epi-506 in patients with metastatic castration-resistant prostate cancer
- 作者：Maurice-Dror Corinne;Le Moigne Ronan;Vaishampayan UlkaMontgomery Robert B.Gordon Michael S.Hong Nan HyungDiMascio LeahPerabo FrankChi Kim N.
- 期刊名称：《Investigational new drugs.》 | 2022年第2期
- Prostate cancer;
- EPI-506;
- EPI-002;
- Androgen receptor;
- N-terminal domain of the androgen receptor;
- -aniten;
- ABIRATERONE ACETATE;
- MECHANISMS;
- ACTIVATION;
- SURVIVAL;
94.Comparison of safety outcomes of anticancer drugs in Japanese and non-Japanese patients in multi-regional clinical trials: meta-analysis of safety profiles

机译：Comparison of safety outcomes of anticancer drugs in Japanese and non-Japanese patients in multi-regional clinical trials: meta-analysis of safety profiles
- 作者：Tamai Toshiyuki;Narukawa Mamoru
- 期刊名称：《Investigational new drugs.》 | 2023年第3期
- Safety profile;
- Adverse events;
- Japanese;
- Cancer;
- Meta-analysis;
- Regional difference;
- TOXICITY;
95.A phase 1 study of intravenous mitazalimab, a CD40 agonistic monoclonal antibody, in patients with advanced solid tumors

机译：A phase 1 study of intravenous mitazalimab, a CD40 agonistic monoclonal antibody, in patients with advanced solid tumors
- 作者：Moreno Victor;Perets Ruth;Peretz-Yablonski TamarFourneau NeleGirgis SuzetteGuo YueHellemans PeterVerona RalucaPendas NataliaXia QiGeva RavitCalvo Emiliano
- 期刊名称：《Investigational new drugs.》 | 2023年第1期
- CD40 agnostic monoclonal antibody;
- Mitazalimab;
- Pharmacokinetics;
- Pharmacodynamics;
- Safety;
- DACETUZUMAB SGN-40;
- ANTI-CD40 ANTIBODY;
- IMMUNE MODULATION;
- CELL;
- PATHWAY;
- COMBINATION;
- GEMCITABINE;
- CP-870;
- 893;
- HELP;
96.IL-10 contributes to gemcitabine resistance in extranodal NK/T-cell lymphoma cells via ABCC4

机译：IL-10 contributes to gemcitabine resistance in extranodal NK/T-cell lymphoma cells via ABCC4
- 作者：Huo Jia;Fu Lijun;Jin MengyuanLi ZhaomingZhang Mingzhi
- 期刊名称：《Investigational new drugs.》 | 2022年第3期
- Extranodal NK;
- T-cell lymphoma;
- IL-10;
- Multidrug resistance;
- Gemcitabine;
- ATP-binding cassette (ABC) protein family;
- INTERLEUKIN-10 EXPRESSION;
- SERUM-LEVELS;
- NASAL;
- INFLAMMATION;
97.A phase II study of tarloxotinib (a hypoxia activated prodrug of a pan-erb tyrosine kinase inhibitor) in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or skin

机译：A phase II study of tarloxotinib (a hypoxia activated prodrug of a pan-erb tyrosine kinase inhibitor) in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or skin
- 作者：McLean Luke S.;Morris Tessa A.;Gramza AnnLiu StephenKhan Saad A.Colevas A. DimitriosPearce TillmanRischin Danny
- 期刊名称：《Investigational new drugs.》 | 2022年第4期
98.Biological evaluation of complexes of cyclopentadienyl M(CO)(3)(+) (M = Re, Tc-99m) with high blood-brain barrier penetration potential as brain cancer agents

机译：Biological evaluation of complexes of cyclopentadienyl M(CO)(3)(+) (M = Re, Tc-99m) with high blood-brain barrier penetration potential as brain cancer agents
- 作者：Mavroidi B.;Kaminari A.;Makrypidi K.Shegani A.Bouziotis P.Pirmettis IPapadopoulos M.Sagnou M.Pelecanou M.
- 期刊名称：《Investigational new drugs.》 | 2022年第3期
99.Rare ocular toxicity induced by pertuzumab/QL1209 in healthy chinese subjects: case reports and whole-exome sequencing analysis

机译：Rare ocular toxicity induced by pertuzumab/QL1209 in healthy chinese subjects: case reports and whole-exome sequencing analysis
- 作者：Ma Junlong;Chen Wenjing;Hu ZhanqingHuang JieGuo ChengxianZou ChanYang Guoping
- 期刊名称：《Investigational new drugs.》 | 2022年第4期
- Pertuzumab;
- Ocular toxicity;
- Breast cancer;
- WES;
- Genetic mechanisms;
- GROWTH-FACTOR RECEPTOR;
- 1ST FDA APPROVAL;
- BREAST-CANCER;
- TARGETED AGENTS;
- CDH23 MUTATIONS;
- TRASTUZUMAB;
- THERAPY;
- COMPLICATIONS;
- RESISTANCE;
- DOCETAXEL;
100.CD25-targeted antibody-drug conjugate camidanlumab tesirine for relapsed or refractory classical Hodgkin lymphoma

机译：CD25-targeted antibody-drug conjugate camidanlumab tesirine for relapsed or refractory classical Hodgkin lymphoma
- 作者：Xu Bo;Li Shaoqian;Kang BoFan ShangzhiHe ZunboZhou Jiecan
- 期刊名称：《Investigational new drugs.》 | 2022年第6期
- Camidanlumab tesirine;
- Classic Hodgkin lymphoma;
- Relapsed or refractory;
- Antibody drug conjugate;
- CD25;
- OPEN-LABEL;
- MULTICENTER;

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有出版物经营许可证

客服微信
服务号